Research Focus
Thomas Reiberger is a physician scientist focusing on clinically-relevant research questions for patients with liver disease. His HEPEX lab investigates novel treatment strategies for liver fibrosis and portal hypertension targeting vascular abnormalities (Reiberger, Journal of Hepatology, 2009), nuclear receptor signaling (Schwabl, Journal of Hepatology, 2017), or the dysregulated nitric oxide - soluble guanylate cyclase (sGC) pathway (Schwabl, Scientific Reports, 2018).
Thomas Reiberger is also the clinical director of the Liver Outpatient Clinic and the Vienna Hepatic Hemodynamic Laboratory at the Division of Gastroenterology & Hepatology, where he leads translational and clinical studies in advanced liver disease.
Main Research Interests
- Liver fibrogenesis and inflammation
- Portal hypertension
- Vascular liver diseases
Biosketch
Thomas Reiberger joined CeMM in November 2018 as an adjunct PI. After obtaining his MD at the Medical University of Vienna, he was a postdoc at the Department of Pathophysiology at MedUni Vienna, focusing on ex-situ liver perfusion and studying hepatocyte oxidative stress and biliary transporters. During his residency for internal medicine, Reiberger pursued a career as a physician-scientist while conducting translational studies on portal hypertension, liver fibrosis, and viral hepatitis. In addition to his clinical activities, he established the Vienna Hepatic Experimental Hemodynamic (HEPEX) Laboratory at MedUni Vienna. The main mission of his HEPEX research team is the exploration of novel treatment options for liver fibrosis and portal hypertension including anti-angiogenic drugs, FXR agonists, modulators of the soluble guanylate cyclase, and integrin inhibitors. In 2011, he received his venia docendi and in 2012 he obtained his board certification for internal medicine. After another postdoctoral fellowship in the United States from 2012 to 2015, Thomas Reiberger joined the faculty of the Division of Gastroenterology and Hepatology at MedUni Vienna. He conducted seminal clinical studies in the field of liver cirrhosis and portal hypertension. Thomas Reiberger is also the director of the clinical program for advanced chronic liver disease and transplant hepatology at the Vienna General Hospital and the coordinator of the Rare Liver Disease (RALID) Center of the European Reference Network (ERN) RARE-LIVER at the Vienna General Hospital.
Top 5 Publications
-
de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII – renewing consensus in portal hypertension. J Hepatol. 2022;76(4):959-974. doi:10.1016/j.jhep.2021.12.022. (published paper)
-
Chen Y, Ramjiawan RR, Reiberger T, Ng MR, Hato T, Huang Y, et al. CXCR4 inhibition in tumor microenvironment facilitates anti–programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice. Hepatology. 2015;61(5):1591-1602. doi:10.1002/hep.27665. (published paper)
-
Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation. J Hepatol. 2024;81(5):895-910. doi:10.1016/j.jhep.2024.06.016. (published paper)
-
Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol. 2013;58(5):911-921. doi:10.1016/j.jhep.2012.12.011. (published paper)
-
Costa D, Simbrunner B, Jachs M, et al. Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. J Hepatol. 2021;74(4):819-828. doi:10.1016/j.jhep.2020.10.004. (published paper)
Please visit Thomas Reiberger's Google Scholar profile for a complete list of publications.
